<DOC>
	<DOCNO>NCT02075840</DOCNO>
	<brief_summary>This randomize , active control , multicenter phase III open-label study design evaluate efficacy safety alectinib compare crizotinib treatment participant treatment-naive anaplastic lymphoma kinase-positive ( ALK-positive ) advance non-small cell lung cancer ( NSCLC ) . Participants randomize 1:1 ratio receive either alectinib , 600 milligram ( mg ) orally twice daily ( BID ) , crizotinib , 250 mg orally BID . Participants receive treatment disease progression , unacceptable toxicity , consent withdrawal death . The study expect last approximately 42 month .</brief_summary>
	<brief_title>A Study Comparing Alectinib With Crizotinib Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis advanced recurrent ( Stage IIIB amenable multimodality treatment ) metastatic ( Stage IV ) NSCLC ALKpositive assess Ventana immunohistochemistry ( IHC ) test Life expectancy least 12 week Eastern cooperative oncology group performance status ( ECOG PS ) 02 Participants prior systemic treatment advance recurrent ( Stage IIIB amenable multimodality treatment ) metastatic ( Stage IV ) NSCLC Adequate renal , hematologic function Participants must recover effect major surgery significant traumatic injury least 28 day first dose study treatment Measurable disease response evaluation criterion solid tumor ( RECIST ) version 1.1 ( v1.1 ) prior administration study treatment Prior brain leptomeningeal metastasis allow asymptomatic ( e.g. , diagnose incidentally study baseline ) Negative pregnancy test females child bear potential Use highly effective contraception define study protocol Participants previous malignancy within past 3 year Any gastrointestinal ( GI ) disorder liver disease National cancer institute common terminology criterion adverse event ( NCI CTCAE ) ( version 4.0 ) Grade 3 high toxicity due prior therapy ( e.g. , radiotherapy ) ( exclude alopecia ) History organ transplant Coadministration anticancer therapy administer study Participants baseline QTc great ( &gt; ) 470 millisecond symptomatic bradycardia Recipient strong/potent cytochrome P4503A inhibitor inducer within 14 day prior first dose end study treatment Recipient drug potential QT interval prolong effect within 14 day prior first dose participant treatment end study crizotinibtreated participant History hypersensitivity additives alectinib crizotinib drug formulation Pregnancy lactation Any clinically significant disease condition ( history ) could interfere , treatment might interfere , conduct study absorption oral medication would , opinion principal investigator , pose unacceptable risk participant study Any psychological , familial , sociological , geographical condition potentially hamper compliance study protocol requirement and/or followup procedure ; condition discuss participant trial entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>